Influenza vaccination represents one of the most cost-effective treatment modalities available to the older adult population.
New long-acting therapeutics are changing the way hemophilia is managed, creating more choice and better treatment compliance.
Improving clinical trial enrollment numbers is a key challenge to advancing research, but a host of solutions suggests a new era of patient engagement and patient-focused clinical trials.
Usually developing following trauma, complex regional pain syndrome (CRPS) has been postulated to be associated with distal degeneration of small-diameter peripheral axons.
Baxalta’s BAX 855, a pegylated full-length recombinant factor VIII (rFVIII) based on the licensed rFVIII product Advate, was designed to increase half-life and potentially reduce the frequency of prophylactic infusions while maintaining hemostatic efficacy.
Investigators at Vanderbilt University Medical Center retrospectively extracted data from medical records of IBD patients treated with intravenous immune globulin (IVIG) used to treat these difficult cases.
The efficacy of Baxter International’s investigational recombinant von Willebrand factor (rVWF) was rated “excellent” (96.9%) or “good” (3.1%) for treatment of 192 bleeding events in 22 patients with severe von Willebrand disease who were enrolled in a Phase 3 clinical trial.
Will the evolving therapeutic guidelines for treating diabetes, as well as managing its risks and complications, stem the tide of this costly and sometimes deadly disease?
In results from a Phase 3b trial in 168 patients needing urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy, 78 patients (90 percent) treated with CSL Behring’s four-factor prothrombin complex concentrate (Kcentra; 4F-PCC) achieved effective hemostasis, compared with 61 patients (75 percent) treated with plasma.
A single-center proof-of-concept study was conducted to learn whether intravenous immunoglobulin (IVIG) can control acute cutaneous lupus erythematosus (CLE) and thus replace current systemic immunosuppressive therapy that causes severe side effects and adverse reactions.
In the debate between personal freedom and government mandates, healthcare professionals are a reliable resource for vaccine information.
With an estimated 79 million Americans currently infected with HPV and an additional 14 million infections occurring each year, why are U.S. vaccination rates stagnantly low?